Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies

Therapeutic options for treating advanced melanoma are progressing rapidly. Although anti-programmed cell death 1 (PD1) antibodies (e.g., nivolumab, pembrolizumab) have been approved as first-line and anchor drugs, respectively, for treating advanced melanoma, the efficacy appears limited as we expe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kambayashi, Yumi, Fujimura, Taku, Hidaka, Takanori, Aiba, Setsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684946/
https://www.ncbi.nlm.nih.gov/pubmed/31417907
http://dx.doi.org/10.3389/fmed.2019.00174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684946/
https://www.ncbi.nlm.nih.gov/pubmed/31417907
http://dx.doi.org/10.3389/fmed.2019.00174

Ejemplares similares